Multifocal Motor Neuropathy: Symptoms, Diagnosis, and a Shifting Treatment Landscape

Multifocal motor neuropathy, or MMN, is a rare disease that most people, including some clinicians, have never heard of. In this article, we'll walk through what MMN actually is, why it's so easy to miss, where treatment stands today, and how patient advocacy is helping close the gaps.

What is multifocal motor neuropathy?

MMN is a rare, chronic autoimmune condition in which the immune system attacks motor nerves carrying signals from the brain to the muscles. Over time, this produces slowly worsening weakness which often starts in one hand or wrist and spreads. 

The "multifocal" in the name refers to that unevenness: MMN doesn't strike the body symmetrically the way many neuropathies do. Someone might lose strength in their right hand while their left hand and both legs stay largely unaffected for years. In nerve conduction studies, this shows up as a hallmark finding called conduction block, essentially a spot where electrical signals traveling down the nerve slow down or stop entirely at a specific, identifiable point.

MMN is very rare, affecting somewhere in the range of 1 in 100,000 people worldwide, with men diagnosed more often than women, typically between their 30s and 50s. Unlike many autoimmune conditions, it isn't inherited, and unlike related conditions in the peripheral neuropathy family, it almost never causes numbness, tingling, or pain. It's a purely motor problem.

MMN symptoms: what it looks like day to day

Because MMN progresses slowly and unevenly, early symptoms are easy to overlook. Patients and their doctors often describe:

• Weakness in one hand or wrist that makes it hard to turn a key, button a shirt, or hold onto small objects
• A "wrist drop," where the wrist can't be extended upward the way it normally would
• Muscle twitching or fine dimpling under the skin (fasciculations), which can look alarming on its own
• Weakness confined to specific nerve territories rather than spreading evenly, so one limb may be affected years before another

MMN does not typically cause sensory loss.. There's no numbness or tingling, and reflexes and muscle tone generally stay normal, even in weakened limbs. That absence of sensory involvement is actually one of the more useful diagnostic clues, because it's one of the main things that separates MMN from conditions with overlapping symptoms.

MMN vs. ALS: why MMN often gets mistaken

The condition MMN is often confused with is ALS. Both conditions cause progressive, asymmetric muscle weakness, and both can start with a disruption to mobility. But MMN has a much better prognosis: it doesn't affect life expectancy, doesn't touch the muscles involved in breathing or swallowing, and, critically, there are effective treatment options available for MMN.. 

Getting to the right diagnosis usually takes a neurologist, a detailed history, and a set of specific tests: electrodiagnostic studies (nerve conduction studies and EMG) to look for conduction block, and blood testing for IgM antibodies to GM1, a marker found in the large majority of MMN patients. Even with these tools available, diagnosis can take years. Survey data collected by patient advocacy groups has repeatedly found that most people with MMN spend well over a year, and often two to three years or more, being treated for the wrong condition before someone identifies MMN correctly.

MMN treatment today: IVIg and what's coming next

For over a decade, the treatment story for MMN has centered on one therapy: intravenous immunoglobulin, or IVIg. Gammagard Liquid 10% has been the only FDA-approved treatment for MMN since 2012, and it remains the standard of care, which is administered monthly in a clinic or hospital setting. IVIg won't reverse existing nerve damage, but it helps many patients regain some strength and slows how quickly the disease progresses. Many patients also have the option of switching to subcutaneous immunoglobulin (SCIg), a self-administered version that some find easier to fit into daily life.

The catch is that IVIg and SCIg are lifelong commitments. Symptoms tend to return once treatment stops, infusions or injections need to be repeated every few weeks, and for some patients, effectiveness can wane over time, requiring higher doses.

That's starting to change. A new class of therapies, complement pathway inhibitors, is moving through clinical trials aimed at a different part of the immune attack than IVIg addresses. Two candidates are furthest along:

• Empasiprubart has produced encouraging early data in a Phase 2 study and has since moved into EMPASSION, a Phase 3 trial comparing it directly against IVIg. Results from the Phase 3 study are expected to be announced sometime at the end of 2026. 
• DNTH103 is being studied in the Phase 2 MoMeNtum trial, with results also expected towards the end of 2026.

Neither of these has reached approval yet, and IVIg remains the only FDA-sanctioned option today. But for a disease that's gone essentially unchanged on the treatment front since 2012, having two different therapies in late-stage development is a meaningful shift for patients.

Why patient registries and real-world data matter

Even with new therapies advancing through trials, most of what's known about how MMN behaves over the long term, across different ages, severities, and treatment histories, still comes from a relatively small pool of patients and studies. Registries and structured patient-reported data help fill that gap. They're what eventually shapes treatment guidelines, supports insurance coverage arguments, and gives researchers a clearer picture of who responds best to which therapy, and why.

If you're living with MMN, details about your own experience — how treatment has affected your strength and function over time, what access barriers you've run into — matter more than they might seem. Novellia's MMN registry is gathering exactly this kind of patient-reported data. Learn more and join the MMN Insights registry to help shape the future of MMN treatment and care.

About Novellia: Novellia is a patient health platform that helps people consolidate their medical records, understand their health data, and participate in research studies on their own terms. Patients stay in control of their data at every step.